Figure 2.
Figure 2. Impact of driver and HMR mutations on OS in study patients population. Kaplan-Meier estimates of OS in patients with a diagnosis of pre-PMF (A) and overt PMF (B) who were stratified according to their CALR type 1/type 1–like, CALR type 2/type 2–like, and JAK2V617F/MPLW515x mutation status. The survival curve of patients negative for the above driver mutations, that is, TN, is also shown. (C-D) The OS by Kaplan-Meier estimates in patients being stratified in a HMR (patients harboring mutation in at least 1 of ASXL1, EZH2, SRSF2, IDH1, or IDH2) and LMR (ie, no mutation in the above genes) category. (C-D) Pre-PMF and overt PMF, respectively. The survival curves of patients with 2 or more mutated genes of the HMR category are also shown.

Impact of driver and HMR mutations on OS in study patients population. Kaplan-Meier estimates of OS in patients with a diagnosis of pre-PMF (A) and overt PMF (B) who were stratified according to their CALR type 1/type 1–like, CALR type 2/type 2–like, and JAK2V617F/MPLW515x mutation status. The survival curve of patients negative for the above driver mutations, that is, TN, is also shown. (C-D) The OS by Kaplan-Meier estimates in patients being stratified in a HMR (patients harboring mutation in at least 1 of ASXL1, EZH2, SRSF2, IDH1, or IDH2) and LMR (ie, no mutation in the above genes) category. (C-D) Pre-PMF and overt PMF, respectively. The survival curves of patients with 2 or more mutated genes of the HMR category are also shown.

Close Modal

or Create an Account

Close Modal
Close Modal